ATE267188T1 - Carbamyloxy-verbindungen zur hemmung der durch vla-4 vermittelten leukozytenadhäsion - Google Patents

Carbamyloxy-verbindungen zur hemmung der durch vla-4 vermittelten leukozytenadhäsion

Info

Publication number
ATE267188T1
ATE267188T1 AT98937052T AT98937052T ATE267188T1 AT E267188 T1 ATE267188 T1 AT E267188T1 AT 98937052 T AT98937052 T AT 98937052T AT 98937052 T AT98937052 T AT 98937052T AT E267188 T1 ATE267188 T1 AT E267188T1
Authority
AT
Austria
Prior art keywords
leukocyte adhesion
mediated leukocyte
carbamyloxy
compounds
inhibiting vla
Prior art date
Application number
AT98937052T
Other languages
English (en)
Inventor
Eugene D Thorsett
Christopher M Semko
Dimitrios Sarantakis
Michael A Pleiss
Anthony Kreft
Andrei W Konradi
Francine S Grant
Darren B Dressen
Susan Ashwell
Reinhardt Bernhard Baudy
Louis John Lombardo
Original Assignee
Elan Pharm Inc
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc, Wyeth Corp filed Critical Elan Pharm Inc
Application granted granted Critical
Publication of ATE267188T1 publication Critical patent/ATE267188T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
AT98937052T 1997-07-31 1998-07-31 Carbamyloxy-verbindungen zur hemmung der durch vla-4 vermittelten leukozytenadhäsion ATE267188T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90442497A 1997-07-31 1997-07-31
US5445397P 1997-08-01 1997-08-01
PCT/US1998/015324 WO1999006390A1 (en) 1997-07-31 1998-07-31 Carbamyloxy compounds which inhibit leukocyte adhesion mediated by vla-4

Publications (1)

Publication Number Publication Date
ATE267188T1 true ATE267188T1 (de) 2004-06-15

Family

ID=26733051

Family Applications (2)

Application Number Title Priority Date Filing Date
AT98937310T ATE236146T1 (de) 1997-07-31 1998-07-31 Alpha-9 integrin antagonisten sowie diese enthaltende anti-inflammatorisch wirkende zusammensetzungen
AT98937052T ATE267188T1 (de) 1997-07-31 1998-07-31 Carbamyloxy-verbindungen zur hemmung der durch vla-4 vermittelten leukozytenadhäsion

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT98937310T ATE236146T1 (de) 1997-07-31 1998-07-31 Alpha-9 integrin antagonisten sowie diese enthaltende anti-inflammatorisch wirkende zusammensetzungen

Country Status (18)

Country Link
EP (3) EP1000051B1 (de)
JP (3) JP4431717B2 (de)
KR (1) KR100639055B1 (de)
CN (1) CN1119340C (de)
AR (1) AR016133A1 (de)
AT (2) ATE236146T1 (de)
AU (2) AU740681B2 (de)
BR (1) BR9811598A (de)
CA (2) CA2290745C (de)
DE (2) DE69824007T2 (de)
ES (1) ES2221183T3 (de)
IL (1) IL133636A0 (de)
NO (1) NO20000413L (de)
NZ (1) NZ502578A (de)
PL (1) PL338521A1 (de)
RU (1) RU2220964C2 (de)
TW (1) TW533211B (de)
WO (2) WO1999006391A1 (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053818A1 (en) * 1997-05-29 1998-12-03 Merck & Co., Inc. Sulfonamides as cell adhesion inhibitors
US6221888B1 (en) 1997-05-29 2001-04-24 Merck & Co., Inc. Sulfonamides as cell adhesion inhibitors
US6903075B1 (en) * 1997-05-29 2005-06-07 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
AU7667498A (en) * 1997-05-30 1998-12-30 Celltech Therapeutics Limited Anti-inflammatory tyrosine derivatives
AU8163398A (en) 1997-06-23 1999-01-04 Pharmacia & Upjohn Company Inhibitors of alpha4beta1mediated cell adhesion
BR9812118A (pt) * 1997-07-31 2000-07-18 Elan Pharm Inc Compostos do tipo 4-amino-fenilalanina que inibem adesão de leucócito mediada por vla-4
US6197794B1 (en) * 1998-01-08 2001-03-06 Celltech Therapeutics Limited Phenylalanine derivatives
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
DE69919334T2 (de) 1998-02-26 2005-08-04 Celltech Therapeutics Ltd., Slough Phenylalaninderivate als inhibitoren von alpha4 integrinen
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
GB9811159D0 (en) 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
GB9811969D0 (en) 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
US6685617B1 (en) 1998-06-23 2004-02-03 Pharmacia & Upjohn Company Inhibitors of α4β1 mediated cell adhesion
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
US6339101B1 (en) * 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
US6333340B1 (en) * 1998-08-14 2001-12-25 Gpi Nil Holdings, Inc. Small molecule sulfonamides for vision and memory disorders
US6337340B1 (en) * 1998-08-14 2002-01-08 Gpi Nil Holdings, Inc. Carboxylic acids and isosteres of heterocyclic ring compounds having multiple heteroatoms for vision and memory disorders
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9821222D0 (en) 1998-09-30 1998-11-25 Celltech Therapeutics Ltd Chemical compounds
GB9825652D0 (en) 1998-11-23 1999-01-13 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
AU2623900A (en) * 1999-01-22 2000-08-07 American Home Products Corporation Compounds which inhibit leukocyte adhesion mediated by vla-4
ATE455106T1 (de) 1999-01-22 2010-01-15 Elan Pharm Inc Acyl derivate zur behandlung von krankheiten die in zusammenhang mit vla-4 stehen
HK1043794A1 (zh) 1999-01-22 2002-09-27 依兰制药公司 抑制vla-4介导的白细胞粘附的稠合环杂芳基和杂环化合物
US6436904B1 (en) 1999-01-25 2002-08-20 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
JP2002538135A (ja) 1999-03-01 2002-11-12 エラン ファーマシューティカルズ，インコーポレイテッド α４β７レセプターアンタゴニストとして有用なα−アミノ酢酸誘導体
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
AU6388500A (en) * 1999-08-05 2001-03-05 Procter & Gamble Company, The Multivalent sulfonamides
US6534513B1 (en) 1999-09-29 2003-03-18 Celltech R&D Limited Phenylalkanoic acid derivatives
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
YU41202A (sh) 1999-12-28 2005-03-15 Pfizer Products Inc. Ne-peptidni inhibitori vezivanja za ćeliju zavisnog od vla-4 korisni pri tretiranju inflamatornih, autoimunih i respiratornih bolesti
US6143776A (en) * 2000-02-02 2000-11-07 Sunesis Pharmaceuticals, Inc. Tosylproline analogs as thymidylate synthase inhibitors
DK1268419T3 (da) * 2000-03-27 2006-10-02 Applied Research Systems Farmaceutisk aktive pyrrolidinderivater som BAX-inhibitorer
DE60120661T2 (de) * 2000-03-27 2007-07-05 Applied Research Systems Ars Holding N.V. Pharmazeutisch wirksame pyrrolidin-derivate als bax-inhibitoren
DE60130910T2 (de) 2000-04-17 2008-07-10 Ucb Pharma, S.A. Enamin-derivate als zell-adhäsionsmoleküle
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
US6740654B2 (en) 2000-07-07 2004-05-25 Celltech R & D Limited Squaric acid derivatives
AU2001275724A1 (en) 2000-08-02 2002-02-13 Celltech R&D Limited 3-substituted isoquinolin-1-yl derivatives
MY129000A (en) 2000-08-31 2007-03-30 Tanabe Seiyaku Co INHIBITORS OF a4 MEDIATED CELL ADHESION
DE10155075A1 (de) * 2001-11-09 2003-05-22 Merck Patent Gmbh Cyclische Sulfonamide
MY140707A (en) 2002-02-28 2010-01-15 Mitsubishi Tanabe Pharma Corp Process for preparing a phenylalanine derivative and intermediates thereof
DE60335175D1 (de) 2002-03-28 2011-01-13 Merck Serono Sa Thiazolidin-carbonsäureamid-derivate als modulatoren des prostaglandin-f-rezeptors
US7638630B2 (en) * 2002-04-30 2009-12-29 Ucb Pharma S.A. 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as VLA-4 inhibitors
TW200307671A (en) 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
TWI281470B (en) 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
CA2514117A1 (en) * 2003-01-24 2004-08-12 Elan Pharmaceuticals, Inc. Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
US7605166B2 (en) * 2003-06-25 2009-10-20 Elan Pharmaceuticals Inc. Methods and compositions for treating rheumatoid arthritis
CA2554188A1 (en) * 2004-01-23 2005-08-04 Elan Pharmaceuticals, Inc. Polyethylene glycol conjugates of heterocycloalkyl carboxamido propanoic acids
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
UA92317C2 (ru) 2004-03-15 2010-10-25 Пи-Ти-Си ТЕРАПЬЮТИКС, ИНК. Производные карболина, пригодные для ингибирования развития кровеносных сосудов
WO2005097162A2 (en) * 2004-04-01 2005-10-20 Elan Pharmaceuticals, Inc. Steroid sparing agents and their use
US7794700B2 (en) * 2004-07-08 2010-09-14 Elan Pharmaceuticals Inc. Multimeric VLA-4 antagonists comprising polymer moieties
WO2006058088A2 (en) 2004-11-23 2006-06-01 Ptc Therapeutics, Inc. Carbazole, carboline and indole derivatives useful in the inhibition of vegf production
JP4871740B2 (ja) * 2005-01-13 2012-02-08 株式会社ジーンテクノサイエンス 抗α９インテグリン抗体とその用途
MX2007014267A (es) * 2005-05-20 2008-02-07 Elan Pharm Inc Derivados de imidazolona fenilamina como antagonistas vla-4.
BRPI0616687A2 (pt) 2005-09-29 2011-06-28 Elan Pharm Inc compostos de pirimidinil amida que inibem a adesão leucocitária mediada por vla-4
CA2624524C (en) 2005-09-29 2014-07-08 Elan Pharmaceuticals, Inc. Carbamate compounds which inhibit leukocyte adhesion mediated by vla-4
CA2643838A1 (en) 2006-02-27 2007-09-07 Elan Pharmaceuticals, Inc. Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by vla-4
WO2008007804A1 (en) 2006-07-12 2008-01-17 Gene Techno Science Co., Ltd. ANTIHUMAN α9 INTEGRIN ANTIBODY AND USE OF THE SAME
WO2008103378A2 (en) 2007-02-20 2008-08-28 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
MX2010011145A (es) 2008-04-11 2011-04-11 Merrimack Pharmaceuticals Inc Enlazadores de la albumina de suero humana y conjugados de la misma.
CN109867630A (zh) * 2013-06-11 2019-06-11 赛尔基因第二国际有限公司 新型glp-1受体调节剂
US20170348375A1 (en) * 2014-12-12 2017-12-07 Commonwealth Scientific And Industrial Research Organisation Dislodgement and release of hsc from the bone marrow stem cell niche using alpha9 integrin antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3432307A1 (de) * 1984-09-03 1986-04-10 Boehringer Ingelheim KG, 6507 Ingelheim Aminosaeurederivate, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen
US6248713B1 (en) * 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
WO1998037914A1 (en) * 1997-02-26 1998-09-03 Toray Industries, Inc. Remedies for hepatitis

Also Published As

Publication number Publication date
WO1999006391A1 (en) 1999-02-11
IL133636A0 (en) 2001-04-30
NO20000413L (no) 2000-03-28
AU8605098A (en) 1999-02-22
EP1452532A1 (de) 2004-09-01
ES2221183T3 (es) 2004-12-16
PL338521A1 (en) 2000-11-06
AR016133A1 (es) 2001-06-20
WO1999006390A1 (en) 1999-02-11
KR100639055B1 (ko) 2006-10-27
EP1000051B1 (de) 2004-05-19
DE69824007T2 (de) 2005-05-25
EP1000051A1 (de) 2000-05-17
AU8584998A (en) 1999-02-22
ATE236146T1 (de) 2003-04-15
DE69812890D1 (de) 2003-05-08
EP0954519B1 (de) 2003-04-02
JP2009269924A (ja) 2009-11-19
BR9811598A (pt) 2000-10-03
CA2267175A1 (en) 1999-02-11
JP2001502361A (ja) 2001-02-20
TW533211B (en) 2003-05-21
CA2290745A1 (en) 1999-02-11
RU2220964C2 (ru) 2004-01-10
NZ502578A (en) 2001-08-31
CA2290745C (en) 2009-09-08
JP4431717B2 (ja) 2010-03-17
JP2001512114A (ja) 2001-08-21
DE69824007D1 (de) 2004-06-24
CA2267175C (en) 2009-12-15
CN1265657A (zh) 2000-09-06
CN1119340C (zh) 2003-08-27
NO20000413D0 (no) 2000-01-27
DE69812890T2 (de) 2003-12-18
AU740681B2 (en) 2001-11-08
EP0954519A1 (de) 1999-11-10
KR20010022373A (ko) 2001-03-15

Similar Documents

Publication Publication Date Title
ATE267188T1 (de) Carbamyloxy-verbindungen zur hemmung der durch vla-4 vermittelten leukozytenadhäsion
IL133640A0 (en) Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4
IL133637A0 (en) Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4
HUP0002682A3 (en) Dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4
IL133639A0 (en) Dipeptide and related compounds which inhibit leukocyte adhesion mediated by vla-4
IL133641A0 (en) Compounds which inhibit leukocyte adhesion mediated by vla-4
DE60036918D1 (de) Verbindungen die die vla-4 vermittelte adhäsion von leukozyten inhibieren
NO20000411D0 (no) 4-amino-fenylalamin forbindelser som inhiberer leukocytt adhesjon mediert av VLA-4
IL133635A0 (en) Benzyl compounds which inhibit leukocyte adhesion mediated by vla-4
ATE299490T1 (de) Multizyklische verbindungen zur hemmung der durch vla-4 vermittelten leukozytenadhäsion
NO972270L (no) Vannfortynnbart beleggingsmateriale for korrosjonsbeskyttelse
DK1004669T3 (da) Hidtil ukendte differentieringsinhibitor
DE69529075D1 (de) Klebende dichtungsmittel-zusammensetzung
FI951130A7 (fi) PNA-synteesi käyttämällä heikkojen happojen suhteen labiilia aminonsuojaryhmää
DK0788496T3 (da) Inhibitorer for syntese af apolipoprotein-B
DE69629047D1 (de) Kristalline olefinharzzusammensetzung
DE69714106D1 (de) Resistzusammenzetzungen zum Metallabscheiden
DE69702247D1 (de) Zusammensetzung zur inhibierung der polymerisierung
KR960009635U (ko) 가로수 보호용 밴드 체결구
HK1026424A (en) Carbamyloxy compounds which inhibit leukocyte adhesion mediated by vla-4
HK1026435A (en) Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4
HK1025976A (en) Dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4
ZA986830B (en) Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4.
FR2733256B1 (fr) Redresseur auto-regule pour la protection cathodique
HK1026434A (en) Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties